<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="203681">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437840</url>
  </required_header>
  <id_info>
    <org_study_id>DAN107606</org_study_id>
    <nct_id>NCT00437840</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809</brief_title>
  <official_title>A Placebo-Controlled, Single-Blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GSK598809 is being developed to facilitate overcoming an addiction to nicotine and to help
      people stop smoking. This study will investigate if GSK598809 is safe and tolerated in
      people who smoke and will also look at blood levels of GSK598809 and nicotine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures: ECG, Vital Signs, Adverse Events</measure>
    <time_frame>for 48 hours after dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Blood levels of GSK598809 and nicotine</measure>
    <time_frame>for 96 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaires on nicotine craving</measure>
    <time_frame>for 24 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tests on cognition (thinking)</measure>
    <time_frame>for 48 hours after dosing</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Smoking</condition>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK598809</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy adult male smoker between the ages of 18 and 50 years

          -  Body weight greater than 50kg and BMI between 18.5-29.9 kg/m2.

          -  No abnormalities on the medical, psychiatric or laboratory evaluation

          -  Smoke on average more than 20 but less that 40 cigarettes per day for the past year
             and not tried to give up in the 3 months before the study.

        Exclusion criteria:

          -  History of psychiatric disorder or sleep disorder.

          -  Receiving treatment for smoking cessation.

          -  Use tobacco products other than cigarettes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>October 9, 2008</lastchanged_date>
  <firstreceived_date>February 20, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>smoking,</keyword>
  <keyword>healthy volunteers,</keyword>
  <keyword>safety,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>pharmacodynamics</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
